A powerful combination of the original GLP1 and the latest technology. Sold in two separate vials so the chemical bonds will not be interrupted between the two compounds. Safe to draw into the same syringe as long as it is IMMEDIATELY given to research subject.
Being sold in two separate vials allows the researcher to control and adjust the dose of each.
Cagrilinitide is a pancreatic hormone that is a dual amylin and calcitonin receptor researched for weight loss management. Research has shown greater weight loss has been achieved with Cagrilinitide vs other GLP1 peptides. It is one of the newest compounds to be used in the battle of obesity.
Semaglutide is a peptide known as a glucagon-like peptide 1 (GLP1)
GLP1 can prompt the body to produce more insulin in response to eating, which reduces blood glucose levels. Semaglutide is researched for the chronic metabolic disease of obesity by interacting with the part of the brain that suppresses appetite and signals fullness. Research has shown that with a reduction in obesity there can be a reduced risk of cancer, diabetes and heart disease.
